Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.

2.

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.

Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN.

Cancer. 2010 Feb 15;116(4):814-21. doi: 10.1002/cncr.24870.

3.

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R.

Gynecol Oncol. 2007 Nov;107(2):173-6.

PMID:
17950384
4.

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD.

Ann Pharmacother. 2003 Oct;37(10):1369-74.

PMID:
14519054
5.

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.

Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, Wadler S, Spiegel G, Arbuck SG.

J Clin Oncol. 2003 Aug 1;21(15):2843-8. Epub 2003 Jun 13.

PMID:
12807937
6.

New targets for cancer chemotherapy.

Murgo AJ, Dancey J, Eckhardt SG, Hidalgo M, Arbuck SG, Zerivitz K, Blaylock BA.

Cancer Chemother Biol Response Modif. 2002;20:239-72. No abstract available.

PMID:
12703208
7.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM.

J Clin Oncol. 2002 Oct 1;20(19):4074-82.

PMID:
12351605
8.

New targets for cancer chemotherapy.

Arbuck SG, Dancey J, Pluda JM, Grochow L, Murgo AJ, Ivy P, Wright J, Blaylock B, Via LE, Sausville EA.

Cancer Chemother Biol Response Modif. 2001;19:237-88. Review. No abstract available.

PMID:
11686017
9.

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients.

Thomas RR, Dahut W, Harold N, Grem JL, Monahan BP, Liang M, Band RA, Cottrell J, Llorens V, Smith JA, Corse W, Arbuck SG, Wright J, Chen AP, Shapiro JD, Hamilton JM, Allegra CJ, Takimoto CH.

Cancer Chemother Pharmacol. 2001 Sep;48(3):215-22.

PMID:
11592343
10.

Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.

Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, Weil C, Winograd B.

Ann Oncol. 2001 Aug;12(8):1067-73.

PMID:
11583187
11.

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ.

Clin Cancer Res. 2001 Jun;7(6):1758-64.

13.

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.

J Clin Oncol. 2001 Apr 15;19(8):2319-33.

PMID:
11304786
14.

Clinical trial designs for cytostatic agents: are new approaches needed?

Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC.

J Clin Oncol. 2001 Jan 1;19(1):265-72. Review.

PMID:
11134222
15.

DNA topoisomerase I poisons.

Takimoto CH, Kieffer LV, Kieffer ME, Arbuck SG, Wright J.

Cancer Chemother Biol Response Modif. 1999;18:81-124. Review. No abstract available.

PMID:
10800479
16.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
17.

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL.

J Clin Oncol. 2000 Feb;18(3):659-67.

PMID:
10653882
18.

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.

Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.

Clin Cancer Res. 1999 Sep;5(9):2381-91.

19.

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.

Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A.

Pharmacol Ther. 1999 May-Jun;82(2-3):285-92. Review.

PMID:
10454206
20.

Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.

Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T.

Clin Cancer Res. 1999 Jul;5(7):1723-30.

21.

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma.

Pazdur R, Medgyesy DC, Winn RJ, Dakhil SR, Moore DF Jr, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL.

Invest New Drugs. 1998-1999;16(4):341-6.

PMID:
10426669
22.

An overview of topoisomerase I-targeting agents.

Arbuck SG, Takimoto CH.

Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12. Review.

PMID:
9779876
23.

National Cancer Institute Clinical Trials Program in Colorectal Cancer.

Conley BA, Kaplan RS, Arbuck SG.

Cancer Chemother Pharmacol. 1998;42 Suppl:S75-9. Review.

PMID:
9750034
24.

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.

Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S.

Cancer Chemother Pharmacol. 1998;42 Suppl:S54-9.

PMID:
9750030
25.

Clinical applications of the camptothecins.

Takimoto CH, Wright J, Arbuck SG.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19. Review.

PMID:
9748525
26.

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA.

J Clin Oncol. 1998 Sep;16(9):2986-99.

PMID:
9738567
27.

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.

Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S.

Cancer Res. 1998 Aug 1;58(15):3248-53.

28.

Clinical status and optimal use of topotecan.

Takimoto CH, Arbuck SG.

Oncology (Williston Park). 1997 Nov;11(11):1635-46; discussion 1649-51, 1655-7. Review.

29.

Accelerated titration designs for phase I clinical trials in oncology.

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC.

J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47.

PMID:
9262252
30.

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.

Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL, Winn R.

J Clin Oncol. 1997 Aug;15(8):2905-9.

PMID:
9256134
31.

A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.

Grem JL, McAtee N, Murphy RF, Balis FM, Cullen E, Chen AP, Hamilton JM, Steinberg SM, Quinn M, Sorensen JM, Arbuck SG, Lawrence D, Pang J, Allegra CJ.

Clin Cancer Res. 1997 Jul;3(7):1125-34.

32.

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.

J Clin Oncol. 1997 Apr;15(4):1492-501.

PMID:
9193345
33.

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.

Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA.

Semin Oncol. 1997 Apr;24(2):219-40. Review.

PMID:
9129691
34.

DNA topoisomerase I inhibitors.

Takimoto CH, Kieffer LV, Arbuck SG.

Cancer Chemother Biol Response Modif. 1997;17:80-113. Review. No abstract available.

PMID:
9551210
35.

New drugs in non-Hodgkin's lymphoma.

Arbuck SG, Sorensen JM, Christian MC, Ho P, Pluda JM, Cheson BD.

Ann Oncol. 1997;8 Suppl 1:119-28. Review.

PMID:
9187445
36.

Clinical pharmacology of 9-aminocamptothecin.

Takimoto CH, Dahut W, Harold N, Nakashima H, Lieberman R, Liang MD, Arbuck SG, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL.

Ann N Y Acad Sci. 1996 Dec 13;803:324-6. No abstract available.

PMID:
8993530
37.

9-Aminocamptothecin and beyond. Preclinical and clinical studies.

Potmesil M, Arbuck SG, Takimoto CH, Liebes L, Hochster H.

Ann N Y Acad Sci. 1996 Dec 13;803:231-46. Review. No abstract available.

PMID:
8993517
38.

Camptothecin and its analogs. An overview of their potential in cancer therapeutics.

Muggia FM, Dimery I, Arbuck SG.

Ann N Y Acad Sci. 1996 Dec 13;803:213-23. Review.

PMID:
8993515
39.
40.

Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.

Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, O'Dwyer PJ.

Eur J Cancer. 1996 Apr;32A(4):631-5.

PMID:
8695266
41.

Paclitaxel: current developmental approaches of the National Cancer Institute.

Arbuck SG.

Semin Oncol. 1995 Dec;22(6 Suppl 15):55-63.

PMID:
8643972
42.

Clinical trials referral resource. Myelodysplastic syndromes.

Cheson BD, Arbuck SG, Phillips PH.

Oncology (Williston Park). 1995 Sep;9(9):821-2, 825. No abstract available.

PMID:
8562324
43.

Clinical trials referral resource. Trials of topotecan.

Cheson BD, Phillips PH, Arbuck SG.

Oncology (Williston Park). 1995 Mar;9(3):220, 224-6, 228. No abstract available.

PMID:
7669515
44.

Seizures associated with leucovorin administration in cancer patients.

Meropol NJ, Creaven PJ, Petrelli NJ, White RM, Arbuck SG.

J Natl Cancer Inst. 1995 Jan 4;87(1):56-8. No abstract available.

PMID:
7666465
45.

Options for primary chemotherapy of epithelial ovarian cancer: taxanes.

Trimble EL, Arbuck SG, McGuire WP.

Gynecol Oncol. 1994 Dec;55(3 Pt 2):S114-21. Review.

PMID:
7835794
46.

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.

Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, et al.

J Clin Oncol. 1994 Mar;12(3):560-8.

PMID:
8120554
47.

Paclitaxel (Taxol) in breast cancer.

Arbuck SG, Dorr A, Friedman MA.

Hematol Oncol Clin North Am. 1994 Feb;8(1):121-40. Review.

PMID:
7908664
48.

Paclitaxel: what schedule? What dose?

Arbuck SG.

J Clin Oncol. 1994 Feb;12(2):233-6. No abstract available.

PMID:
7509379
49.

Clinical development of anticancer agents from natural products.

Parkinson DR, Arbuck SG, Moore T, Pluda JM, Christian MC.

Stem Cells. 1994 Jan;12(1):30-43.

PMID:
7908243
50.

Clinical trials referral resource. Clinical trials with paclitaxel in metastatic breast cancer.

Cheson BD, Abrams JS, Arbuck SG, Phillips PH.

Oncology (Williston Park). 1994 Jan;8(1):72-3, 76-7. No abstract available.

PMID:
7907222

Supplemental Content

Loading ...
Support Center